| Demonstrated oncogenic role for NOTCH1 in Chronic Myelogenous Leukemia (CML) and BCR-ABL disruption of NOTCH1-CCN3 signalling may contribute to the pathogenesis of CML. | leukemia, |
| Sustained Notch1 expression is one key event implicated in the arsenite human skin carcinogenic effect, also provides mechanistic insights into the molecular aspects that determine whether Notch signaling will be oncogenic or tumor suppressive. | skin, |
| miR-139-5p plays a pivotal role in colon cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis and cell cycle arrest by targeting oncogenic NOTCH1 | colorectal, |
| Study identified many previosly unreported human T cell acute lymphoblastic leukemia-specific long noncoding RNAs that are key downstream targets of oncogenic Notch1. | leukemia, |
| The proteins DLK1 and DLK2 modulate NOTCH1-dependent proliferation and oncogenic potential of human SK-MEL-2 melanoma cells. | skin, |
| HPV-positive oral tumors with an activated Notch1 allele had high cell proliferation and tumor growth rates. Notch1 loss sped invasive tumor growth. Though Notch1 is a tumor suppressor in mouse skin, oncogenes perturbing Notch1 expression promoted tumors. | skin, |
| MIRN30 microRNA, human. MiR-30a lessens cellular malignancy by antagonising oncogene Notch1 and plays an effective prognostic role in invasive urothelial carcinoma of the bladder | bladder, |
| OIP5 over-expression inhibited hsa-miR-139-5p expression, antagonized its functions and led to the de-repression of its endogenous target NOTCH1, which was a core oncogene in promoting breast cancer progression. | breast, |
| The role of NOTCH1 in chronic lymphocytic leukemia pathogenesis.NOTCH1 target genes include key regulators of B-cell proliferation, survival, and signal transduction. In particular, we show that NOTCH1 transactivates MYC via binding to B-cell-specific regulatory elements, thus implicating this oncogene in chronic lymphocytic leukemia development. | leukemia, |
| Findings support that Notch1/NR4A2 co-regulate HCC cell functions by playing oncogenic roles and regulating the associated downstream signaling pathways. | liver, |
| NOTCH1 may play an oncogenic role in gastric cancer. Inhibition of NOTCH1 can efficiently attenuate gastric cancer cell progression, probably in part through cross-talking with ERK1/2 signaling pathway. | gastric, |
| Oncogenic Ras increases levels and activity of the intracellular form of wild-type Notch-1, and upregulates Notch ligand Delta-1 and also presenilin-1, a protein involved in Notch processing, through a p38-mediated pathway. | None |
| Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. | None |
| Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. | None |
| Ccr7 gene expression is controlled by the activity of the T-ALL oncogene Notch1 and is expressed in human tumours carrying Notch1-activating mutations | None |
| Notch1 may be an anti-oncogene in ESCC and affects cell differentiation in early stage of the malignancy. The Notch1 pathway might play a key role in microvascular angiogenesis. | None |
| This review focuses on the molecular basis of NOTCH1-induced transformation, the mechanisms of action of oncogenic NOTCH1 and clinical significance of NOTCH1 mutations in T-ALL. Review. | None |
| inhibition of two oncogenic pathways (AURKA and NOTCH-1) by small-molecular inhibitors induced significant growth arrest in NK-cell lines | None |
| Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. | None |
| results provide further insight on the mechanisms that control the activation of oncogenic NOTCH1 mutants and identify ADAM10 as potential therapeutic target for the inhibition of oncogenic NOTCH1 in T-ALL | None |